Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(3.04)
# 1,407
Out of 4,996 analysts
107
Total ratings
40.59%
Success rate
12.81%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $2.70 | +2,344.44% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.57 | +1,992.05% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $3.02 | +462.91% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.61 | +583.23% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $76.63 | -34.75% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.32 | +1,187.88% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $220 | $3.86 | +5,599.48% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $2.99 | +3,478.60% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.33 | +952.63% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $1.97 | +3,301.02% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $3.95 | +988.61% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.49 | +227.87% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.73 | +334.78% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $5.27 | +184.63% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $10.67 | +96.81% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $5.80 | +555.17% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.73 | +5,399.04% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $4.02 | +1,143.78% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $5.86 | +1,845.39% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $5.81 | +3,342.34% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.41 | +574.49% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $14.44 | +128.53% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $22.39 | +78.65% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.44 | +2,469.44% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $6.94 | +361.10% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $22.17 | +247.32% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.11 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $32.80 | +52.44% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $5.07 | +550.89% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $9.78 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $4.46 | +482.96% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $167.82 | -83.32% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.44 | +15,525.00% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $12.53 | +67.60% | 2 | Jul 12, 2017 |
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $2.70
Upside: +2,344.44%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.57
Upside: +1,992.05%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $3.02
Upside: +462.91%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.61
Upside: +583.23%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $76.63
Upside: -34.75%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.32
Upside: +1,187.88%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $220
Current: $3.86
Upside: +5,599.48%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $2.99
Upside: +3,478.60%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.33
Upside: +952.63%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $1.97
Upside: +3,301.02%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $3.95
Upside: +988.61%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $5.49
Upside: +227.87%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.73
Upside: +334.78%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $5.27
Upside: +184.63%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $10.67
Upside: +96.81%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $5.80
Upside: +555.17%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.73
Upside: +5,399.04%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $4.02
Upside: +1,143.78%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $5.86
Upside: +1,845.39%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $5.81
Upside: +3,342.34%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $14.44
Upside: +128.53%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $22.39
Upside: +78.65%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.44
Upside: +2,469.44%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $6.94
Upside: +361.10%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $22.17
Upside: +247.32%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $12.11
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $32.80
Upside: +52.44%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $5.07
Upside: +550.89%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $9.78
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $4.46
Upside: +482.96%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $167.82
Upside: -83.32%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.44
Upside: +15,525.00%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $12.53
Upside: +67.60%